| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | 19.05% | Stephens & Co. | → $82 | Initiates Coverage On | → Equal-Weight |
| 08/08/2023 | 16.14% | DA Davidson | $93 → $80 | Maintains | Neutral |
| 07/31/2023 | 35.02% | DA Davidson | $75 → $93 | Maintains | Neutral |
| 05/02/2023 | 3.08% | DA Davidson | $94 → $71 | Maintains | Neutral |
| 02/22/2023 | 36.47% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 53.89% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 303.6% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 117.77% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 411.03% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 395.06% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 406.68% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 473.46% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 338.44% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 284.73% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 246.98% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 197.62% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 138.1% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | 24.85% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | 20.5% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | 7.43% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 88.73% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 213.59% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy |
What is the target price for Medifast (MED)?
The latest price target for Medifast (NYSE: MED) was reported by Stephens & Co. on October 13, 2023. The analyst firm set a price target for $82.00 expecting MED to rise to within 12 months (a possible 19.05% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medifast (MED)?
The latest analyst rating for Medifast (NYSE: MED) was provided by Stephens & Co., and Medifast initiated their equal-weight rating.
When is the next analyst rating going to be posted or updated for Medifast (MED)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
Is the Analyst Rating Medifast (MED) correct?
While ratings are subjective and will change, the latest Medifast (MED) rating was a initiated with a price target of $0.00 to $82.00. The current price Medifast (MED) is trading at is $68.88, which is within the analyst's predicted range.